Kamaljit Kaur

Dr. Kamaljit Kaur

Department of Biomedical & Pharmaceutical Sciences, School of Pharmacy, Chapman University, Rinker Health Science Campus, Irvine, United States
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MAMona Alas
Mona Alas
ASAzam Saghaeidehkordi
Azam Saghaeidehkordi
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur

4 October 2016 in Nature Communications
Verified
Journal Article
Open access
HEHashem Etayash
Hashem Etayash
MKM. F. Khan
M. F. Khan
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur
TTThomas Thundat
Thomas Thundat
In the fight against drug-resistant bacteria, accurate and high-throughput detection is essential. Here, a bimaterial microcantilever with an embedded microfluidic channel with internal surfaces chemically or physically functionalized with receptors selectively captures the bacteria passing through the channel. Bacterial adsorption inside the cantilever results in changes in the resonance frequency (mass) and cantilever deflection (adsorption stress). The excitation of trapped bacteria using infrared radiation (IR) causes the cantilever to deflect in proportion to the infrared absorption of the bacteria, providing a nanomechanical infrared spectrum for selective identification. We demonstrate the in situ detection and discrimination of Listeria monocytogenes at a concentration of single cell per μl. Trapped Escherichia coli in the microchannel shows a distinct nanomechanical response when exposed to antibiotics. This approach, which combines enrichment with three different modes of detection, can serve as a platform for the development of a portable, high-throughput device for use in the real-time detection of bacteria and their response to antibiotics.

22 February 2012 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DRDharmendra Raghuwanshi
Dharmendra Raghuwanshi
VMVivek Mishra
Vivek Mishra
DDDipankar Das
Dipankar Das
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur
MSMavanur R. Suresh
Mavanur R. Suresh

25 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HHHanieh Hossein-Nejad-Ariani
Hanieh Hossein-Nejad-Ariani
EAEmad Althagafi
Emad Althagafi
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur
The efficacy of chemotherapy for cancer treatment can be increased by targeted drug delivery to the cancer cells. This is particularly important for triple negative breast cancer (TNBC) for which chemotherapy is a major form of treatment. Here we designed and screened a library of 30 peptides starting with a previously reported epidermal growth factor receptor (EGFR) targeting peptide GE11 (YHWYGYTPQNVI). A direct peptide array-whole cell binding assay, where the peptides are conjugated to a cellulose membrane, was used to identify four peptides with enhanced binding to TNBC cells. Next, the four peptides were synthesized as FITC-labelled soluble peptides to study their direct uptake by TNBC cells using flow cytometry. The results showed that peptide analogue 22 had several fold higher uptake by the TNBC cells compared to the lead peptide GE11. The specific uptake of the peptide analogue 22 was confirmed by competition experiment using pure EGF protein. Further, peptide 22 showed dose dependent uptake by the TNBC MDA-MB-231 cells (105) with uptake saturating at around 2 μM peptide concentration. Thus, peptide 22 is a promising EGFR specific TNBC cell binding peptide that can be conjugated directly to a chemotherapeutic drug or to nanoparticles for targeted drug delivery to enhance the efficacy of chemotherapy for TNBC treatment.

5 October 2015 in Scientific Reports
Verified
Journal Article
Open access
HEHashem Etayash
Hashem Etayash
KJKeren Jiang
Keren Jiang
SASarfuddin Azmi
Sarfuddin Azmi
TTThomas Thundat
Thomas Thundat
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur
Ligand-directed targeting and capturing of cancer cells is a new approach for detecting circulating tumor cells (CTCs). Ligands such as antibodies have been successfully used for capturing cancer cells and an antibody based system (CellSearch®) is currently used clinically to enumerate CTCs. Here we report the use of a peptide moiety in conjunction with a microcantilever array system to selectively detect CTCs resulting from cancer, specifically breast cancer. A sensing microcantilever, functionalized with a breast cancer specific peptide 18-4 (WxEAAYQrFL), showed significant deflection on cancer cell (MCF7 and MDA-MB-231) binding compared to when exposed to noncancerous (MCF10A and HUVEC) cells. The peptide-functionalized microcantilever allowed efficient capture and detection of cancer cells in MCF7 spiked human blood samples emulating CTCs in human blood. A detection limit of 50–100 cancer cells mL−1 from blood samples was achieved with a capture yield of 80% from spiked whole blood samples. The results emphasize the potential of peptide 18-4 as a novel peptide for capturing and detecting cancer cells in conjunction with nanomechanical cantilever platform. The reported peptide-based cantilever platform represents a new analytical approach that can lead to an alternative to the various detection platforms and can be leveraged to further study CTCs.

1 June 2018 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
TKTushar Kim
Tushar Kim
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur